bioRxivMicrobiologyPreprint
A multi-dimensional, time-lapse, high content screening platform applied to schistosomiasis drug discovery
S. Chen, B. M. Suzuki, J. Dohrmann, R. Singh, M. R. Arkin, C. R. Caffrey
Abstract
Approximately 10% of the worlds population is at risk of schistosomiasis, a disease of poverty caused by the Schistosoma parasite. To facilitate drug discovery for this complex flatworm, we developed an automated high-content screen to quantify the multidimensional responses of Schistosoma mansoni post-infective larvae (somules) to chemical insult. We describe an integrated platform to process worms at scale, collect time-lapsed, bright-field images, segment highly variable and touching worms, and then store, visualize, and query dynamic phenotypes. To demonstrate the methodology, we treated somules with seven drugs that generated diverse responses and evaluated 45 static and kinetic response descriptors relative to concentration and time. For compound screening, we used the Mahalanobis distance to compare multidimensional phenotypic effects induced by 1,323 approved drugs. Overall, we characterize both known anti-schistosomals and identify new bioactives. Apart from facilitating drug discovery, the multidimensional quantification provided by this platform will allow mapping of chemistry to phenotype.
- organism: mouse
- assay: imaging
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Self-Purifying Microfluidic System for Identifying Drugs Acting Against Adult Schistosomes
V. Girod, M.-J. Ghoris, … J. Vicogne·bioRxiv·Apr 4, 2022
- A novel cell-free method to culture Schistosoma mansoni from cercariae to juvenile worm stages for in vitro drug testing
S. Frahm, A. Anisuzzaman, … C. Prazeres da Costa·bioRxiv·Jun 7, 2018
- A genome-scale drug discovery pipeline uncovers new therapeutic targets and a unique p97 allosteric binding site in Schistosoma mansoni
D.R. Stephens, Ho Yee Joyce Fung, … James J. Collins·Proceedings of the National Academy of SciencesPeer-reviewed·Aug 29, 2025
- Unveiling mode of action of anthelmintics in Caenorhabditis elegans with SydLab™, an on-a-chip automated and high-content screening system.
Thomas B. Duguet, Coralie Belgrano, … Lucien Rufener·bioRxiv·May 15, 2025
- The repositioning of epigenetic probes/inhibitors identifies new anti-schistosomal lead compounds and chemotherapeutic targets
K. Whatley, G. Padalino, … K. F. Hoffmann·bioRxiv·Aug 8, 2019
- In silico REPOSITIONING OF APPROVED DRUGS AGAINST Schistosoma mansoni ENERGY METABOLISM TARGETS
Nicole Melo Calixto, Daniela Braz dos Santos, … Lourival de Almeida Silva·PLoS ONEPeer-reviewed·Dec 31, 2018